NCCN 2013 Congress Series™: Utilizing Guidelines to Customize Patient Care in Breast Cancer

Philadelphia, PA US
October 10, 2013

This congress is an educational program that addresses health care professionals' need to be educated on current and emerging evidenced-based scientific data for accurate and timely clinical evaluation of patients with breast cancer, including the management of early stage and advanced disease. Participants will learn how to implement the NCCN Guidelines recommendations into their practice and gain a clear understanding of the most current treatment recommendations for breast cancer.

Target Audience

This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this educational activity, learners will be able to:

CLINICAL EVALUATION OF PATIENTS

  • Identify the strengths and limitations of breast cancer imaging modalities such as MRI and PET/CT scanning in early diagnosis through state IV or recurrent disease. 
  • Select patients for whom PET/CT imaging may be an appropriate supplement to standard imaging in the staging of disease.
  • Interpret and use nationally recognized quality control recommendations on ER/PR and HER-2 testing in breast cancer patients.

MANAGEMENT OF EARLY STAGE DISEASE

  • Evaluate the duration of endocrine therapy in the adjuvant setting and the choice of endocrine therapy in the metastatic setting for patients with hormone receptor positive disease.
  • List the benefits and risks of adjuvant chemotherapy regimens used in various breast cancer subtypes and the role of gene-based assays in determining the need for chemotherapy.
  • Identify patients likely to benefit from oral chemotherapy and provide education and assessment of compliance to ensure maximum clinical benefit.

MAKING EVIDENCE-BASED TREATMENT DECISIONS IN ADVANCED BREAST CANCER

  • Describe the management of long term bone health in patients undergoing prolonged endocrine therapy.
  • Summarize the considerations in the use of hormonal or cytotoxic therapy with or without targeted therapy and use of single agent versus combination therapy.
  • Assess available evidence to evaluate toxicity and efectiveness of therapy in patients with metastatic disease.
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca LP
  • Eisai Inc.
  • Genentech, USA
  • Genomic Health, Inc.
  • Novartis Pharmaceuticals Corporation
Course summary
Available credit: 
  • 2.25 Participation
  • 2.33 Nurse
  • 2.25 Pharmacist
  • 2.25 Physician
Course opens: 
10/09/2013
Course expires: 
01/17/2014
Event starts: 
10/10/2013 - 5:30pm
Event ends: 
10/10/2013 - 8:00pm
Cost:
$0.00
Sheraton Philadelphia Downtown
201 North 17th Street
Philadelphia, PA 19103
United States

Benjamin O. Anderson, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Harold J. Burstein, MD, PhD
Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center

Lori J. Goldstein, MD
Fox Chase Cancer Center

View the complete agenda

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation details.

Available Credit

  • 2.25 Participation
  • 2.33 Nurse
  • 2.25 Pharmacist
  • 2.25 Physician

Accreditation Period

Course opens: 
10/09/2013
Course expires: 
01/17/2014

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing